{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:19Z","timestamp":1792783339123,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","id":[{"id":"https:\/\/ror.org\/00q1fsf04","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03785-z","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:23:00Z","timestamp":1789975380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease"],"prefix":"10.1007","author":[{"given":"Michael","family":"Kreuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Matthew","family":"Kottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Coeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Kanakapura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schlecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"2","key":"3785_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7861\/clinmedicine.17-2-146","volume":"17","author":"TA Mikolasch","year":"2017","unstructured":"Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung disease. Clin Med (Lond). 2017;17(2):146\u201353.","journal-title":"Clin Med (Lond)"},{"issue":"153","key":"3785_CR2","doi-asserted-by":"publisher","first-page":"190109","DOI":"10.1183\/16000617.0109-2019","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev. 2019;28(153):190109.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"3785_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","volume":"80","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3785_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4046\/trd.2023.0119","volume":"87","author":"HK Kang","year":"2024","unstructured":"Kang HK, Song JW. Progressive pulmonary fibrosis: where are we now? Tuberc Respir Dis. 2024;87(2):123\u201333.","journal-title":"Tuberc Respir Dis"},{"issue":"8","key":"3785_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jfma.2015.10.008","volume":"115","author":"MJ Hsieh","year":"2016","unstructured":"Hsieh MJ, Yang TM, Tsai YH. Nutritional supplementation in patients with chronic obstructive pulmonary disease. J Formos Med Assoc. 2016;115(8):595\u2013601.","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"3785_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/nu12041131","volume":"12","author":"P Faverio","year":"2020","unstructured":"Faverio P, Bocchino M, Caminati A, et al. Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12041131.","journal-title":"Nutrients"},{"issue":"1","key":"3785_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02277-2","volume":"23","author":"A Kalininskiy","year":"2022","unstructured":"Kalininskiy A, Rackow AR, Nagel D, Croft D, McGrane-Minton H, Kottmann RM. Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respir Res. 2022;23(1):377.","journal-title":"Respir Res"},{"key":"3785_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111964","volume":"108","author":"M Holst","year":"2023","unstructured":"Holst M, Nielsen C, Sorensen LF, et al. A 1-year follow-up study in patients with idiopathic pulmonary fibrosis regarding adverse outcomes to unintended weight loss. Nutrition. 2023;108:111964.","journal-title":"Nutrition."},{"issue":"4","key":"3785_CR9","first-page":"671","volume":"81","author":"VI Barcos","year":"2021","unstructured":"Barcos VI, Enghelmayer JI. Nutrition in idiopathic pulmonary fibrosis: The great forgotten? Medicina (B Aires). 2021;81(4):671\u20133.","journal-title":"Medicina (B Aires)."},{"key":"3785_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nut.2018.12.008","volume":"62","author":"S Jouneau","year":"2019","unstructured":"Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition. 2019;62:115\u201321.","journal-title":"Nutrition"},{"issue":"1","key":"3785_CR11","doi-asserted-by":"publisher","first-page":"00443-2021","DOI":"10.1183\/23120541.00443-2021","volume":"8","author":"P Faverio","year":"2022","unstructured":"Faverio P, Fumagalli A, Conti S, et al. Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study. ERJ Open Res. 2022. https:\/\/doi.org\/10.1183\/23120541.00443-2021.","journal-title":"ERJ Open Res"},{"issue":"4","key":"3785_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000490355","volume":"96","author":"Y Nakatsuka","year":"2018","unstructured":"Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96(4):338\u201347.","journal-title":"Respiration"},{"issue":"3","key":"3785_CR13","doi-asserted-by":"publisher","first-page":"1801289","DOI":"10.1183\/13993003.01289-2018","volume":"52","author":"J Pugashetti","year":"2018","unstructured":"Pugashetti J, Graham J, Boctor N, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01289-2018.","journal-title":"Eur Respir J"},{"issue":"10","key":"3785_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221905","volume":"14","author":"T Kulkarni","year":"2019","unstructured":"Kulkarni T, Yuan K, Tran-Nguyen TK, et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One. 2019;14(10):e0221905.","journal-title":"PLoS One"},{"issue":"1","key":"3785_CR15","doi-asserted-by":"publisher","first-page":"2311845","DOI":"10.1080\/07853890.2024.2311845","volume":"56","author":"X He","year":"2024","unstructured":"He X, Ji J, Liu C, et al. Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Ann Med. 2024;56(1):2311845.","journal-title":"Ann Med."},{"issue":"22","key":"3785_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"22","key":"3785_CR17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"8","key":"3785_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/resp.14550","volume":"28","author":"T Ogura","year":"2023","unstructured":"Ogura T, Nakazawa A. Unveiling the importance of evaluating the nutritional status in idiopathic pulmonary fibrosis patients with antifibrotic agent introduction. Respirology. 2023;28(8):699\u2013700.","journal-title":"Respirology"},{"issue":"3","key":"3785_CR19","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","volume":"59","author":"KR Flaherty","year":"2022","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59(3):2004538.","journal-title":"Eur Respir J"},{"issue":"9","key":"3785_CR20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3785_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3785_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1165\/rcmb.2024-0614OC","volume":"73","author":"D Reininger","year":"2025","unstructured":"Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700\u201312.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3785_CR23","unstructured":"U.S. Food and Drug Administration. JASCAYD\u00ae (nerandomilast tablets), for oral use. 2025 [cited 12 December 2025]; Available from: https:\/\/patient.boehringer-ingelheim.com\/us\/products\/jascayd\/bipdf\/prescribing-information"},{"key":"3785_CR24","unstructured":"Boehringer Ingelheim. JASCAYD\u00ae (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF). 2025 [cited February 2026]; Available from: https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/pulmonary-fibrosis\/jascayd-nerandomilast-approved-china-treatment-idiopathic-pulmonary-fibrosis-ipf"},{"key":"3785_CR25","unstructured":"Boehringer Ingelheim. JASCAYD\u00ae (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China. 2025 [cited February 2026]; Available from: https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/pulmonary-fibrosis\/jascayd-nerandomilast-first-regulatory-approval-ppf-china"},{"issue":"1","key":"3785_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01528-4","volume":"21","author":"S Jouneau","year":"2020","unstructured":"Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21(1):312.","journal-title":"Respir Res"},{"issue":"Supplement_1","key":"3785_CR27","first-page":"A7788","volume":"201","author":"S Jouneau","year":"2020","unstructured":"Jouneau S, Crestani B, Thibault R, et al. Clinical outcomes at 1 year in patients with idiopathic pulmonary fibrosis (IPF) stratified by annualized weight loss and baseline body mass index (BMI): a post-hoc analysis from Ascend, Capacity, Inspire, and Riff. Am J Respir Crit Care Med. 2020;201(Supplement_1):A7788\u2013A88.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3785_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000518855","volume":"101","author":"S Jouneau","year":"2022","unstructured":"Jouneau S, Crestani B, Thibault R, et al. Post hoc analysis of clinical outcomes in placebo-and pirfenidone-treated patients with IPF stratified by BMI and weight loss. Respiration. 2022;101(2):142\u201354.","journal-title":"Respiration"},{"issue":"1","key":"3785_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02371-z","volume":"24","author":"M Kreuter","year":"2023","unstructured":"Kreuter M, Bendstrup E, Jouneau S, et al. Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial. Respir Res. 2023;24(1):71.","journal-title":"Respir Res"},{"issue":"2","key":"3785_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","volume":"193","author":"U Costabel","year":"2016","unstructured":"Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178\u201385.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"3785_CR31","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"key":"3785_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01418-5","volume":"21","author":"AA Kanjrawi","year":"2021","unstructured":"Kanjrawi AA, Mathers L, Webster S, Corte TJ, Carey S. Nutritional status and quality of life in interstitial lung disease: a prospective cohort study. BMC Pulm Med. 2021;21:51.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3785_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.resinv.2020.10.002","volume":"59","author":"A Sekine","year":"2021","unstructured":"Sekine A, Wasamoto S, Hagiwara E, et al. Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity. Respir Investig. 2021;59(2):247\u201351.","journal-title":"Respir Investig"},{"key":"3785_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101839","volume":"59","author":"A Perelas","year":"2019","unstructured":"Perelas A, Glennie J, van Kerkhove K, et al. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2019;59:101839.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"3785_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1019-9","volume":"20","author":"SA Guler","year":"2019","unstructured":"Guler SA, Hur SA, Lear SA, Camp PG, Ryerson CJ. Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respir Res. 2019;20(1):56.","journal-title":"Respir Res"},{"issue":"1","key":"3785_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22449-w","volume":"12","author":"TH Kim","year":"2022","unstructured":"Kim TH, Shin Y-Y, Kim H-J, et al. Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone. Sci Rep. 2022;12(1):17397.","journal-title":"Sci Rep"},{"issue":"1","key":"3785_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34071-7","volume":"16","author":"S Goda","year":"2025","unstructured":"Goda S, Yamada T, Goto Y, et al. Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan. Sci Rep. 2025;16(1):3947.","journal-title":"Sci Rep"},{"issue":"4","key":"3785_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.resinv.2024.04.011","volume":"62","author":"H Yamakawa","year":"2024","unstructured":"Yamakawa H, Sato S, Ohta H, et al. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease. Respir Investig. 2024;62(4):551\u20137.","journal-title":"Respir Investig"},{"issue":"1","key":"3785_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-04048-3","volume":"25","author":"K Yazaki","year":"2025","unstructured":"Yazaki K, Matsuyama M, Satoh H, et al. Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases. BMC Pulm Med. 2025;25(1):564.","journal-title":"BMC Pulm Med"},{"key":"3785_CR40","unstructured":"Highlights Report Cystic Fibrosis in Europe Facts and Figures (2023). European Cystic Fibrosis Society Patient Registry."},{"issue":"7","key":"3785_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/thx.2004.035220","volume":"60","author":"JJ Swigris","year":"2005","unstructured":"Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60(7):588\u201394.","journal-title":"Thorax."},{"issue":"1","key":"3785_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03262-9","volume":"24","author":"S Stoltefuss","year":"2024","unstructured":"Stoltefuss S, Leuschner G, Milger K, et al. Assessing health-related quality of life in patients with interstitial lung diseases. BMC Pulm Med. 2024;24(1):452.","journal-title":"BMC Pulm Med"},{"key":"3785_CR43","unstructured":"Action for Pulmonary Fibrosis. Eating well with pulmonary fibrosis. [cited March 2026]; Available from: https:\/\/www.actionpf.org\/information-support\/eating-well-with-pulmonary-fibrosis"},{"key":"3785_CR44","unstructured":"Pulmonary Fibrosis News. Importance of proper nutrition and diet for PF patients: a nutritionist\u2019s view. 2019 [cited March 2026]; Available from: https:\/\/pulmonaryfibrosisnews.com\/news\/proper-nutrition-vital-pf-patients-nutritionists-view\/"},{"key":"3785_CR45","unstructured":"American Lung Association. Nutrition and Pulmonary Fibrosis. 2024 [cited March 2026]; Available from: https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pulmonary-fibrosis\/patients\/living-well-with-pulmonary-fibrosis\/nutrition"},{"key":"3785_CR46","unstructured":"Pulmonary Fibrosis 360. A guide to support patients with interstitial lung diseases (ILDs) who have nutritional concerns. 2025 [cited March 2026]; Available from: https:\/\/www.pulmonaryfibrosis360.com\/uk\/bipdf\/ild-nutrition-digital-guide"},{"issue":"2","key":"3785_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/nu11020329","volume":"11","author":"L Guti\u00e9rrez-Carrasquilla","year":"2019","unstructured":"Guti\u00e9rrez-Carrasquilla L, S\u00e1nchez E, Hern\u00e1ndez M, et al. Effects of Mediterranean diet and physical activity on pulmonary function: a cross-sectional analysis in the ILERVAS project. Nutrients. 2019;11(2):329.","journal-title":"Nutrients"},{"key":"3785_CR48","first-page":"380","volume":"30","author":"L Yazdanpanah","year":"2016","unstructured":"Yazdanpanah L, Paknahad Z, Moosavi AJ, Maracy MR, Zaker MM. The relationship between different diet quality indices and severity of airflow obstruction among COPD patients. Med J Islam Rep Ir\u00e1n. 2016;30:380.","journal-title":"Med J Islam Rep Ir\u00e1n."},{"key":"3785_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-015-1450-x","volume":"15","author":"M Sorl\u00ed-Aguilar","year":"2015","unstructured":"Sorl\u00ed-Aguilar M, Mart\u00edn-Luj\u00e1n F, Santigosa-Ayala A, et al. Effects of Mediterranean diet on lung function in smokers: a randomised, parallel and controlled protocol. BMC Public Health. 2015;15:1\u20137.","journal-title":"BMC Public Health"},{"issue":"5","key":"3785_CR50","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/nu13051716","volume":"13","author":"C Espirito Santo","year":"2021","unstructured":"Espirito Santo C, Caseiro C, Martins MJ, Monteiro R, Brandao I. Gut microbiota, in the halfway between nutrition and lung function. Nutrients. 2021.https:\/\/doi.org\/10.3390\/nu13051716.","journal-title":"Nutrients"},{"issue":"12","key":"3785_CR51","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1002\/acr.25176","volume":"75","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, McMahan ZH, Smith V, et al. Risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease treated with nintedanib in the randomized, placebo-controlled SENSCIS trial. Arthritis Care Res. 2023;75(12):2501\u20137.","journal-title":"Arthritis Care Res."},{"issue":"3","key":"3785_CR52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.chest.2025.09.021","volume":"169","author":"R Kahai","year":"2026","unstructured":"Kahai R, Castelli G, Danzo F, et al. Specialist dietary intervention in patients with fibrotic interstitial lung disease experiencing unintentional weight loss: a pilot randomized controlled trial. Chest. 2026;169(3):687\u201397.","journal-title":"Chest."},{"issue":"6","key":"3785_CR53","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1183\/09031936.00070914","volume":"44","author":"AM Schols","year":"2014","unstructured":"Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014;44(6):1504\u201320.","journal-title":"Eur Respir J"},{"issue":"4","key":"3785_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/MCP.0000000000000684","volume":"26","author":"L Nelkine","year":"2020","unstructured":"Nelkine L, Vrolijk MF, Drent M, Bast A. Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2020;26(4):363\u201371.","journal-title":"Curr Opin Pulm Med"},{"issue":"17","key":"3785_CR55","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/ijms21176051","volume":"21","author":"J Mercader-Barcelo","year":"2020","unstructured":"Mercader-Barcelo J, Truyols-Vives J, Rio C, Lopez-Safont N, Sala-Llinas E, Chaplin A. Insights into the role of bioactive food ingredients and the microbiome in idiopathic pulmonary fibrosis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21176051.","journal-title":"Int J Mol Sci"},{"key":"3785_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.clnesp.2022.03.035","volume":"49","author":"M Yavari","year":"2022","unstructured":"Yavari M, Mousavi SAJ, Janani L, Feizy Z, Vafa M. Effects of supplementation of vitamins D, C and E on idiopathic pulmonary fibrosis (IPF): a clinical trial. Clin Nutr ESPEN. 2022;49:295\u2013300.","journal-title":"Clin Nutr ESPEN"},{"issue":"6","key":"3785_CR57","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.chest.2024.12.018","volume":"167","author":"YJ Jung","year":"2025","unstructured":"Jung YJ, Lee MJ, Kim EH, Bae SJ, Kim HK. Association of lung function with visceral adiposity and skeletal muscle mass considering myosteatosis. Chest. 2025;167(6):1714\u201326.","journal-title":"Chest"},{"issue":"1","key":"3785_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12931-024-02705-5","volume":"25","author":"M Sridhar","year":"2024","unstructured":"Sridhar M, Bodduluri S, O\u2019Hare L, et al. Association of musculoskeletal involvement with lung function and mortality in patients with idiopathic pulmonary fibrosis. Respir Res. 2024;25(1):81.","journal-title":"Respir Res."},{"issue":"3","key":"3785_CR59","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/resp.12941","volume":"22","author":"O Nishiyama","year":"2017","unstructured":"Nishiyama O, Yamazaki R, Sano H, et al. Fat\u2010free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480\u20135.","journal-title":"Respirology"},{"issue":"1","key":"3785_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001039","volume":"8","author":"FV Machado","year":"2021","unstructured":"Machado FV, Bloem AE, Schneeberger T, et al. Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2021;8(1):e001039.","journal-title":"BMJ Open Respir Res"},{"issue":"17","key":"3785_CR61","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","volume":"83","author":"F Bonella","year":"2023","unstructured":"Bonella F, Spagnolo P, Ryerson C. Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs. 2023;83(17):1581\u201393.","journal-title":"Drugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03785-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:23:06Z","timestamp":1789975386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03785-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":61,"alternative-id":["3785"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03785-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Kreuter reports consultancy for Boehringer Ingelheim, Roche, GlaxoSmithKline, AstraZeneca, Bristol Myers Squibb and Vicore and speaker fees for Boehringer Ingelheim. Matthew Kottman has nothing to declare. Fengming Luo reports consultancy for Boehringer Ingelheim. Tomohiro Handa has received a research grant from FUJIFILM Corporation and Daiichi Sankyo Company Limited and belongs to an endowed department sponsored by Teijin Pharma Limited. Carl Coeck is an employee of Boehringer Ingelheim SComm. Madhu Kanakapura, Christina Schlecker and Ivana Ritter are employees of Boehringer Ingelheim International GmbH. Michael Kreuter, Matthew Kottman, Fengming Luo, Carl Coeck, Madhu Kanakapura, Christina Schlecker, Ivana Ritter, and Tomohiro Handa report medical writing support from Boehringer Ingelheim International GmbH.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The trials reported on here were carried out in accordance with the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocols were approved by an independent ethics committee or institutional review board at each participating centre (Supplementary Material). All patients provided written informed consent before study entry.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}